ImmunoGen Shares Takes Flight On Ovarian Cancer Survival Data


Funding Overview

ImmunoGen (NASDAQ:IMGN) – an underneath the radar, Waltham, Massachusetts based mostly biotech based in 1981 despatched its shareholders into raptures yesterday after publishing new information from its Section 3 MIRASOL examine of its drug ELAHERE, in sufferers with FRα-Constructive, Platinum-Resistant Ovarian Most cancers (“PROC”).

Elahere development strategy

ELAHERE improvement technique (ImmunoGen presentation)

Elahere current guidelines and development program

ImmunoGen affected person alternative forecast for ELAHERE (ImmunoGen presentation)